GD - Online GD Symposium 27th January 2010
Suchen |Inhalt
 Symposium in Bonn
Home
 
 
 
Weitere Links:
 
 
 
 
 
 
 


Development and Regulatory Aspects of Topical Dermatics Today

Organizer:
GD Society for Dermopharmacy
in cooperation with
BfArM Federal Institute for Drugs abd Medical Devices


Program (PDF)

Session 1: Dermatics - a world of its own

Session 2: Identification and production of active pharmaceutical ingredients

Session 3: Characterization of active pharmaceutical ingredients

Session 4: Aspects of formulation

Session 5: Clinical development

Session 1: Dermatics - a world of its own

Session 2: Identification and production of active pharmaceutical ingredients

Sorted by program

Sorted by author

Titel Author
Abstracts of sessions 1 and 2  
Which dermatics do we have? H. F. Merk, Aachen
Which dermatics do we need?
T. Luger, Münster
The regulatory framework for preclinical research
T. Zapf, Bonn
Target identification: general aspects and sphingosine-1-phosphate receptors as an example
Lead optimization: general aspects and MAP kinase inhibitors for psoriasis as an example
Target identification and lead optimization: Fungal secreted aspartic proteinase inhibitors as a paradigm
Production of active pharmaceutical ingredients: general aspects and sphingosine-1-phosphate and inhibitors of human polymerase alpha as an example

top

Author Titel
Abstracts of sessions 1 and 2
C. Borelli, München Target identification and lead optimization: Fungal secreted aspartic proteinase inhibitors as a paradigm
B. Kleuser, Potsdam Target identification: general aspects and sphingosine-1-phosphate receptors as an example
S. Laufer, Tübingen Lead optimization: general aspects and MAP kinase inhibitors for psoriasis as an example
T. Luger, Münster Which dermatics do we need?
H. F. Merk, Aachen Which dermatics do we have?
T. Zapf, Bonn The regulatory framework for preclinical research
R. Zuhse, Luckenwalde Production of active pharmaceutical ingredients: general aspects and sphingosine-1-phosphate and inhibitors of human polymerase alpha as an example

top

Session 3: Characterization of active pharmaceutical ingredients

Session 4: Aspects of formulation

Sorted by program

Sorted by author

Titel Author
Abstracts for sessions 3 and 4

top

Author Titel

top

Session 5: Clinical development

Sorted by program

Sorted by author

Titel Author
Abstracts of session 5
Optimizing the development plan through scientific advice process
Human toxicology/phase I studies
Phase II trials
Phase III trials
Phase IV trials

top

Author Titel
 

top

 

   Copyright © 2000 - 2011
Institute for Dermopharmacy GmbH
webmaster@gd-online.de
Impressum
Haftungsausschluss